TY  - JOUR
AU  - Korićanac, Lela
AU  - Žakula, Jelena
AU  - Petrović, Ivan M.
AU  - Valastro, Lucia M.
AU  - Cirrone, Giuseppe Antonio Pablo
AU  - Cuttone, Giacomo
AU  - Ristić-Fira, Aleksandra
PY  - 2010
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4021
AB  - Background: Metastatic melanoma is one of the most aggressive tumours and is also very resistant to current therapeutic approaches. The aim of this investigation was the in vitro study of the anti-proliferative effects of fotemustine (FM; 100 and 250 mu M), bevacizumab (5 mu g/ml) and proton irradiation (12 and 16 Gy) on resistant HTB140 human melanoma cells. Methods: Viability was estimated by sulphorhodamine B assay, while cell proliferation was analyzed by 5-bromo-2-deoxyuridine assay. Cell cycle distribution and apoptosis were examined using flow cytometry. Results: Cell viability and proliferation were reduced after all applied treatments. The level of apoptosis significantly increased after treatment with FM, protons or a combination of all agents, while the apoptotic index ranged from 1.2 to 9.2. Proton irradiation, as well as combined treatment with bevacizumab and protons or 100 mu M FM, bevacizumab and protons, have reduced melanoma cell proliferation through the induction of G1 phase arrest. Single FM (250 mu M) or bevacizumab treatment and their combination, as well as the joint application of these 2 agents with protons, reduced cell proliferation and provoked G2 phase accumulation. Conclusion: The analyzed treatments reduced cell viability and proliferation, triggered G1 or G2 cell cycle phase accumulation and stimulated apoptotic cell death. Copyright (C) 2010 S. Karger AG, Basel
T2  - Chemotherapy
T1  - Anti-Tumour Activity of Fotemustine and Protons in Combination with Bevacizumab
VL  - 56
IS  - 3
SP  - 214
EP  - 222
DO  - 10.1159/000316333
ER  - 

@article{
author = "Korićanac, Lela and Žakula, Jelena and Petrović, Ivan M. and Valastro, Lucia M. and Cirrone, Giuseppe Antonio Pablo and Cuttone, Giacomo and Ristić-Fira, Aleksandra",
year = "2010",
abstract = "Background: Metastatic melanoma is one of the most aggressive tumours and is also very resistant to current therapeutic approaches. The aim of this investigation was the in vitro study of the anti-proliferative effects of fotemustine (FM; 100 and 250 mu M), bevacizumab (5 mu g/ml) and proton irradiation (12 and 16 Gy) on resistant HTB140 human melanoma cells. Methods: Viability was estimated by sulphorhodamine B assay, while cell proliferation was analyzed by 5-bromo-2-deoxyuridine assay. Cell cycle distribution and apoptosis were examined using flow cytometry. Results: Cell viability and proliferation were reduced after all applied treatments. The level of apoptosis significantly increased after treatment with FM, protons or a combination of all agents, while the apoptotic index ranged from 1.2 to 9.2. Proton irradiation, as well as combined treatment with bevacizumab and protons or 100 mu M FM, bevacizumab and protons, have reduced melanoma cell proliferation through the induction of G1 phase arrest. Single FM (250 mu M) or bevacizumab treatment and their combination, as well as the joint application of these 2 agents with protons, reduced cell proliferation and provoked G2 phase accumulation. Conclusion: The analyzed treatments reduced cell viability and proliferation, triggered G1 or G2 cell cycle phase accumulation and stimulated apoptotic cell death. Copyright (C) 2010 S. Karger AG, Basel",
journal = "Chemotherapy",
title = "Anti-Tumour Activity of Fotemustine and Protons in Combination with Bevacizumab",
volume = "56",
number = "3",
pages = "214-222",
doi = "10.1159/000316333"
}

Korićanac, L., Žakula, J., Petrović, I. M., Valastro, L. M., Cirrone, G. A. P., Cuttone, G.,& Ristić-Fira, A.. (2010). Anti-Tumour Activity of Fotemustine and Protons in Combination with Bevacizumab. in Chemotherapy, 56(3), 214-222.
https://doi.org/10.1159/000316333

Korićanac L, Žakula J, Petrović IM, Valastro LM, Cirrone GAP, Cuttone G, Ristić-Fira A. Anti-Tumour Activity of Fotemustine and Protons in Combination with Bevacizumab. in Chemotherapy. 2010;56(3):214-222.
doi:10.1159/000316333 .

Korićanac, Lela, Žakula, Jelena, Petrović, Ivan M., Valastro, Lucia M., Cirrone, Giuseppe Antonio Pablo, Cuttone, Giacomo, Ristić-Fira, Aleksandra, "Anti-Tumour Activity of Fotemustine and Protons in Combination with Bevacizumab" in Chemotherapy, 56, no. 3 (2010):214-222,
https://doi.org/10.1159/000316333 . .

TY  - JOUR
AU  - Ristić-Fira, Aleksandra
AU  - Korićanac, Lela
AU  - Žakula, Jelena
AU  - Valastro, Lucia M.
AU  - Iannolo, Gioacchin
AU  - Privitera, Giuseppe
AU  - Cuttone, Giacomo
AU  - Petrović, Ivan M.
PY  - 2009
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3702
AB  - Background: Considering that HTB140 melanoma cells have shown a poor response to either protons or alkylating agents, the effects of a combined use of these agents have been analysed. Methods: Cells were irradiated in the middle of the therapeutic 62 MeV proton spread out Bragg peak (SOBP). Irradiation doses were 12 or 16 Gy and are those frequently used in proton therapy. Four days after irradiation cells were treated with fotemustine (FM) or dacarbazine (DTIC). Drug concentrations were 100 and 250 mu M, values close to those that produce 50% of growth inhibition. Cell viability, proliferation, survival and cell cycle distribution were assessed 7 days after irradiation that corresponds to more than six doubling times of HTB140 cells. In this way incubation periods providing the best single effects of drugs (3 days) and protons (7 days) coincided at the same time. Results: Single proton irradiations have reduced the number of cells to similar to 50%. FM caused stronger cell inactivation due to its high toxicity, while the effectiveness of DTIC, that was important at short term, almost vanished with the incubation of 7 days. Cellular mechanisms triggered by proton irradiation differently influenced the final effects of combined treatments. Combination of protons and FM did not improve cell inactivation level achieved by single treatments. A low efficiency of the single DTIC treatment was overcome when DTIC was introduced following proton irradiation, giving better inhibitory effects with respect to the single treatments. Most of the analysed cells were in G1/S phase, viable, active and able to replicate DNA. Conclusion: The obtained results are the consequence of a high resistance of HTB140 melanoma cells to protons and/or drugs. The inactivation level of the HTB140 human melanoma cells after protons, FM or DTIC treatments was not enhanced by their combined application.
T2  - Journal of Experimental and Clinical Cancer Research
T1  - Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation
VL  - 28
DO  - 10.1186/1756-9966-28-50
ER  - 

@article{
author = "Ristić-Fira, Aleksandra and Korićanac, Lela and Žakula, Jelena and Valastro, Lucia M. and Iannolo, Gioacchin and Privitera, Giuseppe and Cuttone, Giacomo and Petrović, Ivan M.",
year = "2009",
abstract = "Background: Considering that HTB140 melanoma cells have shown a poor response to either protons or alkylating agents, the effects of a combined use of these agents have been analysed. Methods: Cells were irradiated in the middle of the therapeutic 62 MeV proton spread out Bragg peak (SOBP). Irradiation doses were 12 or 16 Gy and are those frequently used in proton therapy. Four days after irradiation cells were treated with fotemustine (FM) or dacarbazine (DTIC). Drug concentrations were 100 and 250 mu M, values close to those that produce 50% of growth inhibition. Cell viability, proliferation, survival and cell cycle distribution were assessed 7 days after irradiation that corresponds to more than six doubling times of HTB140 cells. In this way incubation periods providing the best single effects of drugs (3 days) and protons (7 days) coincided at the same time. Results: Single proton irradiations have reduced the number of cells to similar to 50%. FM caused stronger cell inactivation due to its high toxicity, while the effectiveness of DTIC, that was important at short term, almost vanished with the incubation of 7 days. Cellular mechanisms triggered by proton irradiation differently influenced the final effects of combined treatments. Combination of protons and FM did not improve cell inactivation level achieved by single treatments. A low efficiency of the single DTIC treatment was overcome when DTIC was introduced following proton irradiation, giving better inhibitory effects with respect to the single treatments. Most of the analysed cells were in G1/S phase, viable, active and able to replicate DNA. Conclusion: The obtained results are the consequence of a high resistance of HTB140 melanoma cells to protons and/or drugs. The inactivation level of the HTB140 human melanoma cells after protons, FM or DTIC treatments was not enhanced by their combined application.",
journal = "Journal of Experimental and Clinical Cancer Research",
title = "Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation",
volume = "28",
doi = "10.1186/1756-9966-28-50"
}

Ristić-Fira, A., Korićanac, L., Žakula, J., Valastro, L. M., Iannolo, G., Privitera, G., Cuttone, G.,& Petrović, I. M.. (2009). Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation. in Journal of Experimental and Clinical Cancer Research, 28.
https://doi.org/10.1186/1756-9966-28-50

Ristić-Fira A, Korićanac L, Žakula J, Valastro LM, Iannolo G, Privitera G, Cuttone G, Petrović IM. Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation. in Journal of Experimental and Clinical Cancer Research. 2009;28.
doi:10.1186/1756-9966-28-50 .

Ristić-Fira, Aleksandra, Korićanac, Lela, Žakula, Jelena, Valastro, Lucia M., Iannolo, Gioacchin, Privitera, Giuseppe, Cuttone, Giacomo, Petrović, Ivan M., "Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation" in Journal of Experimental and Clinical Cancer Research, 28 (2009),
https://doi.org/10.1186/1756-9966-28-50 . .